MIDDLETOWN, Conn.--(BUSINESS WIRE)--PursueCare, a leader in virtual addiction treatment, today announced the rollout of RESET® and RESET-O® , the only FDA-authorized prescription digital therapeutics (PDTs) for substance use disorder (SUD) and opioid use disorder (OUD). The groundbreaking app-based digital therapies deliver a self-guided 12-week course of cognitive behavioral therapy (CBT), in which patients are incentivized to complete lessons, adhere to treatment, and abstain from drug use.

康涅狄格州米德尔敦——（商业新闻短讯）——虚拟成瘾治疗领域的领导者追踪中心（PurseeCare）今天宣布推出RESET®和RESET-O®，这是FDA唯一授权用于药物使用障碍（SUD）和阿片类药物使用障碍（OUD）的处方数字治疗（PDT）。基于应用程序的开创性数字疗法提供了为期12周的自我指导的认知行为疗法（CBT），鼓励患者完成课程，坚持治疗并戒毒。

Demonstrated to reduce substance use, increase treatment retention, and reduce overall healthcare costs, the products are positioned to transform addiction treatment..

这些产品已被证明可以减少物质使用，提高治疗保留率，并降低整体医疗成本，这些产品有望改变成瘾治疗。

RESET® and RESET-O® were originally developed and commercialized by Pear Therapeutics, Inc. They were acquired by PursueCare late last year. The company will leverage the PDTs in conjunction with its comprehensive virtual treatment offering, specifically focusing on value-based care arrangements with health plans.

RESET®和RESET-O®最初由Pear Therapeutics，Inc.开发和商业化。它们于去年年底被Purseecare收购。该公司将利用PDTs及其全面的虚拟治疗服务，特别关注基于价值的医疗保健安排和健康计划。

Additionally, PursueCare is establishing programs with partnering clinics to enable delivery of RESET® and RESET-O® to their patients..

此外，PurseeCare正在与合作诊所建立计划，以便向患者提供RESET®和RESET-O®。。

Real-World Impact and Cost Savings

现实世界的影响和成本节约

RESET® and RESET-O® integrate seamlessly with outpatient care, including medications for OUD (MOUD), providing continuous support and personalized progress tracking. By enhancing patient engagement, these PDTs align with value-based care models prioritized by health plans. Data presented by representatives of the Massachusetts state Medicaid program, MassHealth, shows RESET® and RESET-O® users saved Massachusetts $2,011 per user in health care resource related costs, with emergency room visits and hospitalizations reduced by 45% and 64%, respectively..

RESET®和RESET-O®与门诊护理无缝集成，包括OUD药物（MOUD），提供持续支持和个性化进度跟踪。通过增强患者参与度，这些PDT与健康计划优先考虑的基于价值的护理模式保持一致。马萨诸塞州医疗补助计划MassHealth代表提供的数据显示，RESET®和RESET-O®用户为每位用户节省了2011美元的医疗保健资源相关费用，急诊室就诊和住院率分别减少了45%和64%。。

“At PursueCare, we are driven by the belief that everyone deserves accessible, high-quality care that meets them where they are and stays with them through their journey. RESET® and RESET-O® align perfectly with our mission. Digital therapeutics empower individuals to reclaim control over their health, advancing a new standard of care for chronic substance use disorder,” said Nick Mercadante, Founder and Chief Executive Officer of PursueCare..

“在追求中心，我们的信念是，每个人都应该获得可获得的高质量护理，在他们所在的地方与他们见面，并在旅途中与他们一起度过。RESET®和RESET-O®与我们的使命完美契合。数字治疗使个人能够重新控制自己的健康，推动慢性物质使用障碍的新护理标准，”追求中心创始人兼首席执行官尼克·梅卡丹特（Nick Mercadante）表示。。

Comprehensive Virtual Care

全面虚拟护理

PursueCare’s virtual clinic model offers telehealth treatment for opioids, alcohol, stimulants, and other substances through a multidisciplinary care team. Treatment plans include MOUD sometimes referred to as medication-assisted treatment, counseling, psychiatry, targeted case management, treatment for physical health conditions that are common to drug users like Hepatitis C, and pharmacy services.

Purseecare的虚拟诊所模型通过多学科护理团队为阿片类药物、酒精、兴奋剂和其他物质提供远程保健治疗。治疗计划包括有时被称为药物辅助治疗的MOUD，咨询，精神病学，有针对性的病例管理，治疗丙型肝炎等吸毒者常见的身体健康状况，以及药房服务。

Care is delivered through PursueCare’s smart phone app, empowering patients to manage their recovery from anywhere, and its providers to easily engage when needed. “Our team addresses the critical need for accessible addiction treatment,” said Dr. Jason Kirby, DO, MBA, FASAM, PursueCare’s Medical Director.

通过PurseeCare的智能手机应用程序提供护理，使患者能够在任何地方管理他们的康复，并且其提供商可以在需要时轻松参与。“我们的团队解决了对无障碍成瘾治疗的迫切需求，”Jason Kirby博士（DO，MBA，FASAM）说，他是PurseeCare的医学总监。

“RESET® and RESET-O® provide essential tools that keep patients engaged, while the data-driven insights it provides our team promotes personalized, effective care and timely interventions.”.

“RESET®和RESET-O®提供了保持患者参与的基本工具，而它提供的数据驱动见解促进了我们团队的个性化，有效护理和及时干预。”。

Expanding Access Through Partnerships

通过伙伴关系扩大准入

PursueCare partners with health systems and community providers to deliver integrated access to addiction care locally. Screening, interventions, and referrals are integrated at key points like emergency rooms, enabling same-day treatment initiation. Recent research sponsored by the National Institute on Drug Abuse (NIDA) underscores the necessity of an integrated, multidisciplinary approach to improve patient outcomes..

追求与卫生系统和社区提供者合作，在当地提供综合成瘾治疗服务。筛查，干预和转诊在急诊室等关键点进行整合，从而可以在当天开始治疗。由国家药物滥用研究所（NIDA）赞助的最新研究强调了采取综合的多学科方法来改善患者预后的必要性。。

About PursueCare

关于追求

PursueCare provides personalized virtual addiction treatment for individuals across nine states (CT, KY, MA, ME, NH, NJ, OH, PA, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy.

。我们的使命是通过远程保健增加获得慢性病护理的机会。患者与多学科团队合作，提供医疗护理、咨询、精神病学和药房。

FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O® , supports recovery 24/7. We accept private insurance, Medicare, and Medicaid..

FDA授权的数字认知行为疗法RESET®和RESET-O®支持全天候恢复。我们接受私人保险、医疗保险和医疗补助。。

RESET-O® Indications for Use

RESET-O®使用指示

RESET-O® prescription digital therapeutic is a 12-weeks (84 days) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

RESET-O®处方数字治疗是一种为期12周（84天）的软件应用程序，旨在通过提供认知行为疗法来增加门诊治疗中阿片类药物使用障碍（OUD）患者的保留率，作为门诊治疗的辅助手段，包括透粘膜丁丙诺啡和应急管理，适用于目前正在临床医生监督下的18岁或以上患者。

RESET-O® is indicated as a prescription-only digital therapeutic..

RESET-O®表示为仅限处方的数字治疗仪。